Nanotropil Novo, tablets 100 mg 30 pcs

Notropic drug with a pronounced anti-amnesic effect, promotes memory consolidation, facilitates learning, increases the resistance of brain tissue to toxic effects, has anticonvulsant effect.

It has a positive effect on metabolic processes, stimulates redox processes, increases the body’s energy potential by utilizing glucose. It increases the content of noradrenaline, dopamine and serotonin in the brain; it does not influence the content of GABA; it does not bind to GABA and GABA receptors and has no significant effect on spontaneous bioelectrical activity of the brain.

It has no effect on respiration and cardiovascular system, shows no pronounced diuretic effect, has anorexigenic activity with a course of use.

The stimulant effect is manifested by the ability to produce a moderately pronounced effect on motor reactions, increase physical performance, and decrease the severity of the sleeping effects of ethanol and hexobarbital.

The psychostimulant effect is predominant in the ideational sphere.

The adaptogenic action is manifested in increasing the body’s resistance to stress under conditions of excessive mental and physical exertion, fatigue, hypokinesia and immobilization, at low temperatures.

At the time of taking the drug improvement of vision was noted, which is manifested by an increase in visual acuity, brightness and visual fields.

It improves blood supply to the lower extremities.

Stimulates the production of antibodies in response to the introduction of the antigen, which indicates immunostimulatory properties, but at the same time does not promote immediate-type hypersensitivity and does not change the allergic inflammatory skin reaction caused by the introduction of the foreign protein.

With a course of use, drug dependence, tolerance and “withdrawal syndrome” do not develop. The action is seen in a single dose, which is important when using the drug in extreme conditions.

Absorption: Fast absorption. Absolute bioavailability with oral administration is 100%.

Distribution: It penetrates into various organs and tissues, easily passes through the blood-brain barrier. Maximal concentration in blood (Tmax) is reached after 1 hour.

Metabolism: Not metabolized in the body.

Elimation: Period of half-life (T1/2) – 3-5 hours. It is excreted unchanged: about 40% – by kidneys and 60% – in bile and sweat.

Indications

• Diseases of the central nervous system of various origins, especially those associated with metabolic disorders in the brain, intoxication (in particular, in post-traumatic conditions), accompanied by deterioration of intellectual and mnestic functions, decreased motor activity;

• Neurotic conditions, manifested by lethargy, increased exhaustion, decreased psychomotor activity, impaired attention, memory impairment;

• Disorders of the learning process;

• Psychoorganic syndromes, manifested by intellectual-mnestic disorders and apathetic-abulic phenomena, as well as flaccid apathetic states in schizophrenia;

• Convulsive states;

• Obesity (alimentary-constitutional origin);

• Prevention of hypoxia, increasing resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to increase mental and physical performance, correction of circadian biorhythm, inversion of the sleep-wake cycle;

• Chronic alcoholism (in order to reduce intellectual and mental disorders).

Pharmacological effect

A nootropic drug with a pronounced anti-amnesic effect, promotes memory consolidation, facilitates the learning process, increases the resistance of brain tissue to toxic effects, and has an anticonvulsant effect.

It has a positive effect on metabolic processes, stimulates redox processes, and increases the body’s energy potential through the utilization of glucose. Increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA content, does not bind to GABAA and GABAB receptors, and does not have a noticeable effect on the spontaneous bioelectrical activity of the brain.

It has no effect on respiration and the cardiovascular system, exhibits an unpronounced diuretic effect, and has anorexigenic activity when used in a course.

The stimulating effect is manifested in the ability to have a moderately pronounced effect, manifested in relation to motor reactions, increased physical performance, as well as a weakening of the severity of the hypnotic effect of ethanol and hexobarbital.

The psychostimulating effect predominates in the ideational sphere.

The adaptogenic effect manifests itself in increasing the body’s resistance to stress under conditions of excessive mental and physical stress, fatigue, hypokinesia and immobilization, and low temperatures.

While taking the drug, there was an improvement in vision, which manifested itself in an increase in acuity, brightness and visual fields.

Improves blood supply to the lower extremities.

Stimulates the production of antibodies in response to the introduction of an antigen, which indicates immunostimulating properties, but at the same time does not contribute to the development of immediate hypersensitivity and does not change the allergic inflammatory reaction of the skin caused by the introduction of a foreign protein.

With a course of use, drug dependence, tolerance, and “withdrawal syndrome” do not develop. The effect occurs with a single dose, which is important when using the drug in extreme conditions.

Absorption: Rapidly absorbed. Absolute bioavailability after oral administration is 100%.

Distribution: Penetrates various organs and tissues, easily passes through the blood-brain barrier. The maximum concentration in the blood (Tmax) is achieved after 1 hour.

Metabolism: Not metabolized in the body.

Excretion: Half-life (T1/2) – 3-5 hours. Excreted unchanged: approximately 40% by the kidneys and 60% by bile and sweat.

Special instructions

With excessive psycho-emotional exhaustion due to stress and fatigue, chronic insomnia, a single dose of the drug on the first day can cause a sharp need for sleep. Such patients on an outpatient basis should be advised to start a course of taking the drug on non-working days.

Active ingredient

Phenylpiracetam

Composition

1 tablet contains:

active ingredient: phenylpiracetam – 50.00 mg or 100.00 mg;

excipients: povidone K-17, microcrystalline cellulose, sodium carboxymethyl starch, magnesium stearate.

Pregnancy

There are no data on randomized clinical trials of phenylpiracetam in pregnant women, and therefore the use of the drug Nanotropil® is new during pregnancy and breastfeeding is contraindicated.

Contraindications

Hypersensitivity to phenylpiracetam or any excipient in the drug.

Pregnancy and breastfeeding period.

Age under 18 years (due to the lack of clinical data on the effectiveness and safety of phenylpiracetam in this age population).

Side Effects

Insomnia (if the drug is taken later than 15 hours). In some patients, in the first 1-3 days of use, psychomotor agitation, skin hyperemia, a feeling of warmth, and increased blood pressure are possible.

Interaction

Phenylpiracetam may enhance the effects of CNS stimulants and nootropic drugs.

The drug exhibits pronounced antagonism to the cataleptic effect of neuroleptics, and also weakens the severity of the hypnotic effect of ethanol and hexobarbital.

Overdose

There were no cases of overdose.

Treatment: symptomatic therapy.

Storage conditions

In a place protected from light at a temperature not exceeding 30 ° C. Keep out of the reach of children.

Shelf life

3 years.

Manufacturer

Obninsk HFC, Russia